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1 Drug description 
Generic/Brand name:   
Ibritumomab tiuxetan/ Zevalin ® 
Developer/Company:  
Manufacturer of the biological active substance is Biogen IDEC, USA, the 
manufacturer responsible for batch release is Bayer Schering Pharma AG 
[1]. 
Description:  
Ibritumomab tiuxetan (Zevalin ®) is a radioimmunotherapy drug which is 
administered in combination with rituximab. It is the immunoconjugate of 
ibritumomab, a monoclonal antibody, and tiuxetan, a chelator for the ra-
dionucleotide yttrium-90. Zevalin® binds specifically to the antigen CD20 of 
B-lymphocytes which is expressed on pre-B and mature B-lymphocytes and 
on malignant B-lymphocytes. Before ibritumomab tiuxetan can be used, it 
has to be radiolabelled by attaching the radioactive element yttrium-90. The 
monoclonal antibody targets the CD20 antigen and the β-emission from yt-
trium-90 with a mean path length of 5mm results in the induction of cellular 
damage of both targeted and neighbouring cells. In order to deliver the ra-
diation more precisely to the lymphomas, rituximab (in a reduced dose com-
pared to the approved monotherapy) should be used as pre-treatment to 
eliminate circulating CD20 positive B-lymphocytes [1, 2] and to saturate any 
unspecific bindings.  
If ibritumomab tiuxetan is administered as consolidation therapy after re-
mission induction, patients with ≥150,000 platelets per mm³ should receive 
15MBq/kg (megabecquerel per kilogram) body weight up to a maximum of 
1200MBq. Patients with a lower platelet count should not receive ibritumo-
mab tiuxetan at all [1]. This means that marrow infiltration by the lym-
phoma should not exceed 25%.    Rituximab has to be given twice, one week 
before (day 1) and immediately prior (day 7, 8 or 9) to Zevalin® administra-
tion which is given only once as slow intravenous infusion over ten minutes 
[1].  
2 Indication 
Ibritumomab tiuxetan is indicated as consolidation therapy after first remis-
sion induction in patients with follicular lymphoma.  
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3 Burden of disease 
Follicular lymphomas (FL) are the 2nd most common entity among B-cell 
non-Hodgkin’s lymphomas (NHL) which are a heterogeneous group of lym-
phoproliferative disorders. Within NHL, indolent and aggressive lympho-
mas are differentiated, a classification based on differences in prognosis. 
Depending on the number of centroblasts the Revised European-American 
Classification of Lymphoid Neoplasms (REAL) and WHO guidelines clas-
sify FLs into three grades. The majority of FLs are indolent lymphomas 
consistent with grade 1 or 2, whereas aggressive forms are of grade 3a and 3b 
[3, 4].  
Symptoms include enlarged lymph nodes, either isolated or disseminated, 
and the so called B-symptoms which include weight loss, fever or night 
sweats. Besides lymph nodes, the spleen, the bone marrow or the skin are 
most commonly affected. Risk factors are older age, male gender, white eth-
nicity, inherited immune disorders (e.g. hypogammaglobulinemia), auto-
immune diseases, such as Sjögren-syndrome or rheumatoid arthritis, and in-
fections with HIV/AIDS, Epstein-Barr virus or Helicobacter pylori [5].  
In 2006, 991 new NHL cases were diagnosed and 541 NHL related deaths 
occurred in Austria [6].  The International Lymphoma Classification Project 
which evaluated 1,402 lymphoma cases, comprising more than 90% of all 
NHL cases in the United States, identified 22% as being follicular lympho-
mas [4]. Applying the same percentage to the overall NHL incidence in Aus-
tria, indicates 220 follicular lymphoma cases annually. The NHL incidence 
has constantly risen over the last decades, particularly in older people in 
their 60s or 70s, mainly due to a reduction of mortality from other causes 
[4]. Median age at diagnosis is about 65 years [7], a fact related to the high 
probability of co-morbidities [4]. 
To verify diagnosis a biopsy should be performed by reason that therapeutic 
decisions are influenced by the cell of origin, immunophenotype and other 
genetic attributes [4]. Another factor relevant to the choice of treatment is 
whether the disease is localized or advanced, corresponding to Ann Arbor 
stage III or IV. This classification system comprises four stages (I-IV) based 
on the number and regions  of lymph nodes affected, involvement of extra 
lymphatic organs/sites and whether these lesions are on the same side or on 
both sides of the diaphragm [3]. Within these four groups, two subcategories 
(A and B) can be distinguished based on the presence or absence of B-
symptoms.  
Risk factors influencing the prognosis are summarized in the Follicular 
Lymphoma International Prognostic Index (FLIPI) and include age, serum 
lactate dehydrogenase level, disease stage (Ann Arbor), haemoglobin level 
and number of nodal areas affected (≤4 vs >4). Additional to these factors, 
age, performance status, tumour size and the presence of bulky disease are 
known to impact on the prognosis [3]. Depending on the number of risk fac-
tors present, the 10-year survival rate ranges from 40% to 85% [3]. Even 
though patients with FL most often present with disseminated disease [3], 
median survival ranges from 8 to 15 years leading to the annotation of being 
indolent. Relapse to more aggressive forms is possible, resulting in a dimin-
ished median survival of 1 to 2 years after transformation and a 10-year sur-
vival of only 10% to 20% of patients [3].  
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4 Current treatment 
Choice of treatment depends on disease stage, age, co-morbidities and future 
treatment possibilities, such as eligibility for high-dose therapy (e.g. 
autologuous stem cell rescue), and is therefore highly individualized.  
Observation is an option as long as there are none of the following symptoms 
present: ≥3 nodal sites involved, extra-, nodal tumor mass ≥7 cm in diame-
ter, B symptoms, pleural effusions or peritoneal ascites, cytopenias or leu-
kemia.  
 If treatment is indicated, options for both first- and second-line therapy are: 
 Locoregional radiation therapy 
 Chemotherapy (cyclophosphamide, vincristine, doxorubicin, fluda-
rabine, mitoxantrone, chlorambucil, bendamustin in various com-
binations and often including further chemotherapeutic agents like 
etoposide or platinum-derivatives) 
 Immunotherapy (rituximab) 
 Chemo-immunotherapy 
 Radioimmunotherapy (tositumomab (Bexxar®) only available in 
the USA) 
 High dose therapy with autologous or allogeneic stem cell rescue 
(only as second-line treatment) [4].  
The National Cancer Comprehensive Network (NCCN) has given a category 
1 recommendation for cyclophosphamide, doxorubicin, vincristine, predni-
sone (CHOP) + rituximab (R-CHOP), for cylophosphamide, vincristine, 
prednisone (CVP) + rituximab and for chemotherapy followed by radioim-
munotherapy as first-line therapy. Category 1 treatment options for second-
line therapy include fludarabine, cyclophosphamide, mitoxantrone + ri-
tuximab (FCMR) and radioimmunotherapy.  
In addition to these indications, rituximab can also be used as first-line 
maintenance therapy but preferably within clinical trials. Furthermore, it is 
recommended as first-line therapy for elderly or infirm patients who are not 
eligible for chemotherapy and as second-line maintenance therapy [4].   
5 Current regulatory status 
The EMEA granted marketing authorization for ibritumomab tiuxetan   
 for the treatment of adult patients with rituximab relapsed or re-
fractory CD20+ follicular B-cell NHL in January 2004. 
 
 NCCN category 1 = The recommendation is based on high-level evidence, and 
there is uniform NCCN consensus. 
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 for the consolidation therapy after remission induction in previ-
ously untreated patients with follicular lymphoma in April 2008 
[1]. The benefit of Zevalin®  following  rituximab  in  combination 
with chemotherapy has not been established 
  
Indications approved by the U.S. Food and Drug Administration (FDA) are 
 relapsed or refractory, low-grade or follicular B-cell NHL (February 
2002). 
 previously untreated patients with follicular NHL who achieve a 
partial or complete response to first-line chemotherapy (March 
2009) [2].  
 
6  Evidence 
Overall, four studies - one phase III trial and three phase II trials - were 
identified. The former, which compared consolidation therapy of ibritumo-
mab tiuxetan to no further treatment after initial response to first-line che-
motherapy, showed marked improvements for the intervention group as me-
dian progression-free survival (PFS) was prolonged by 23 months. This held 
true, even if patients were stratified according to the extent of their initial 
response. No differences - either for overall survival or for quality of life - 
were found between the intervention and the control group.  
The three phase II studies (without control groups) yielded similar results. 
In patients pre-treated with chemotherapy, complete response rates in-
creased, if ibritumomab tiuxetan was given after initial chemotherapy.  
Overall, adverse events were very common and consisted primarily of tran-
sient myelosuppression. However, only a minority of patients (about 7%) re-
quired hospitalization for the treatment of these toxic effects.  
6.1 Efficacy and safety - Phase III studies  
 
Reference  published [8, 9] NCT00185393  
Sponsor Bayer Schering Pharma AG, Berlin, Germany 
Country International, 77 study centres in 12 European countries (United Kingdom, Bel-
gium, France, Italy, Netherlands, Norway, Denmark, Sweden, Spain, Portugal, 
Germany, Switzerland) and Canada 
Design randomized , open-label, placebo-controlled 
Participants characteristics 414 patients (I=208 vs C=206)  
median age I 55 years (range 29 – 78 years) vs C 53 years (range 27 – 74 years)  
Treatments I(ntervention):  
 
250 mg/m2 body surface area rituximab IV at day -7 and at day 0, followed by 
 
approved by the EMEA 
and the FDA after 
remission induction in 
previously untreated 
patients with FL 
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90Y-ibritumomab tiuxetan 14.8 MBq2/kg (maximal total dose 1.148 MBq) on day 
0 
 
C(ontrol): no treatment 
                                 
In-/exclusion criteria Inclusion criteria: histological confirmed CD20+, grade 1 or 2 follicular lymphoma 
(REAL /WHO classification) , stage III or IV disease at diagnosis, WHO perform-
ance status of 0 to 2, CR/CRu3 or PR4 (International Workshop criteria) after first-
line chemotherapy (chlorambucil, CVP, CHOP, CHOP/-like, fludarabine or rituxi-
mab combinations) administered 6 to 12 weeks before start of the study treat-
ment  
Exclusion criteria: prior radiation therapy or myeloablative therapy, symptomatic 
CNS lymphoma  
Follow-up median observation period of 3.5 years  
Outcomes Primary: overall PFS5, PFS stratified by response to first-line induction therapy 
(i.e. PR, CR/CRu)  
Secondary: PFS based on type of first-line induction therapy, PFS according to 
FLIPI6 scores, improvement in CR rate, overall survival (OS), safety, health-related 
quality of life 
Key results  
 
Primary:  
median PFS overall: I 36.5 months vs C 13.3 months; HR =0.465 (CI: 0.357, 0.605; 
p<0.0001) 
 
median PFS according to response to first-line therapy:  
PR after first-line induction treatment: median PFS time I 29.3 months vs C 
6.2 months, HR=0.304 (CI: 0.213, 0.434; p=<0.0001) 
CR/CRu after first-line induction treatment: median PFS time I 53.9 months 
vs C 29.5                    months; HR=0.613 (CI: 0.410, 0.914; p=0.0154) 
 
 
Secondary:  
- median PFS according to type of first-line therapy: 
Chlorambucil I NR7 vs C 11.9 months, HR8= 0.344 (CI9: 0.150, 0.793; 
p=0.0088) 
CVP/COP: I 28.5 months vs C 7.9 months, HR= 0.383 (CI: 0.235, 0.625; p= 
0.0001) 
CHOP: I 35.9 months vs C 12.5 months, HR= 0.391 (CI: 0.246, 0.622; 
p<0.0001) 
CHOP-like I NR vs C 29.2 months, HR=0.474 (CI: 0.219, 1.029; p=0.0533) 
Fludarabine combination I 41.4 months vs C 24.3 months; HR=0.884 (CI: 
0.283, 2.769; p=0.8332) 
Rituximab combination  I NR vs C NR, HR=0.722 (CI: 0.304, 1.714; 
p=0.4583) 
 
 - median PFS according to FLIPI risk score: 
low I NR vs C 24.1 months, HR 0.599 (CI: 0.357, 1.006; p=0.0502) 
intermediate I 53.9 months vs C 11.3 months, HR=0.227 (CI: 0.134, 0.385; 
p<0.0001) 
high I 23.8 months vs C 6.5 months, HR=0.587 (CI: 0.322, 1.070; p=0.0789)
 
- pts converting from PR after induction therapy to CR/CRu I 77% vs C 17.5% 
 
2 MBq = Mega-Becquerel 
3 CR = complete response, CRu = unconfirmed complete response 
4 PR = partial response 
5 PFS = progression-free survival 
6 FLIPI = Follicular Lymphoma International Prognostic Index 
7 NR = not reached 
8 HR = Hazard Ratio 
9 CI = 95% Confidence Interval 
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(p<0.001) 
 
- no difference in OS between study arms 
 
- health-related quality of life:  
mean EQ-5D10 scores (baseline/final visit): I  0.83/0.84 vs C 0.84/0.83 
mean VAS11-score (baseline/final visit): I 77.52/77.64 vs C 76.57/78.60 
Adverse effects grade 3: 
lymphopenia I 60.3% vs C 10.8%; neuropenia: I 40.2% vs C C 2.0%, throm-
bocytopenia I 58.8% vs C 0%, anemia I 2.9% vs C 0% 
Infections I 6.9% vs C 2.4%, pyrexia I 2.5% vs C 0% 
 
grade 4:  
lymphopenia I 0% vs C 0%, neutropenia I 26.5% vs C 0.5%, thrombocyto-
penia I 2.0% vs C 0%, anemia I 0.5% vs C 0% 
Infections I 1.0% vs C 0%, pyrexia I 0.5% vs C 0% 
 
deaths:  
I 6 pts (1 neutropenic sepsis after subsequent chemotherapy, 1, pancreatic 
carcinoma,1 acute myeloblastic leukemia (AML) , 3 pts due to progressive 
disease) vs C 5 pts (1 sepsis, 4 due to progressive disease)  
 
7.4% of the intervention group required hospitalization because of infections 
1 AML case 2 years after ibritumomab tiuxetan therapy 
Commentary consolidation therapy with ibritumomab tiuxetan in patients achieving an initial 
response to first-line induction treatment is well tolerated with no unexpected 
toxicities and significantly prolongs PFS by 2 years compared with no further 
treatment.  
 
10 EQ-5D = EuroQol-5D 
11 VAS = Visual Analogue Scale 
 
This randomized controlled trial assessed ibritumomab tiuxetan as consoli-
dation therapy in patients after first remission with various chemotherapy 
regimens, including rituximab based regimens. The study population was 
slightly younger than patients usually diagnosed with FL. Baseline charac-
teristics were well balanced within the two groups and consisted of patients 
with FL at Ann Arbor stage III and IV and mainly at low (I 37% vs C 43%) 
or intermediate (I 39% vs C 37%) FLIPI risk.  
Substantial improvements in median PFS were demonstrated for patients 
treated with ibritumomab tiuxetan in comparison to no additional treatment 
(HR=0.47), an effect independent of response to initial treatment. Adverse 
effects, including serious events such as myelosuppression, were more com-
mon in the intervention group (in up to 60% of patients) than in the control 
group, requiring hospitalization in 7% of patients. Six patients died in the 
intervention group and five in the control group.  
Based on the relatively short median follow-up of 3.5 years, improvements in 
overall survival have not been established yet. No differences were observed 
in outcomes associated with health-related quality of life, including pain 
scores. Moreover, only 14% of patients had received rituximab containing 
regimens as first-line therapy which might not reflect standard practice of 
FL treatment [10]. For these patients, treatment with ibritumomab tiuxetan 
in comparison to no treatment did not lead to favourable results in terms of 
PFS.  
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6.2 Efficacy and safety - further studies 
A phase II study [11] evaluated ibritumomab tiuxetan  and extended rituxi-
mab after short-course CHOP-R therapy in 60 previously untreated FL pa-
tients. The study population comprised mainly patients < 60 years (65%) 
with higher stage FL (> 90% stage III or IV) or bulky FL and at intermedi-
ate and high FLIPI risk (75%). In an intention-to-treat analysis, the CR rate 
determined by computer tomography was 40% after CHOP-R and increased 
to 82% with radioimmunotherapy and extended rituximab. During a mean 
estimated follow-up of 19 months, 10 patients progressed of whom 8 had 
previously achieved CR, one PR and one stable disease. Adverse events asso-
ciated with radioimmunotherapy were mostly myelosuppression, leading to 
neutropenia in 51% of patients and to thrombocytopenia in 44% of patients. 
However, only one patient required admission to hospital for the treatment 
of neutropenic fever.  
Zinzani et al.[12] assessed fludarabine and mitoxantrone followed by ibri-
tumomab tiuxetan in previously untreated FL patients. They included 61 
patients with stage III or IV, indolent FL. Consolidation treatment with ibri-
tumomab tiuxetan was administered only, if at least PR was achieved after 
six cycles of chemotherapy with fludarabine and mitoxantrone. Adding ibri-
tumomab tiuxetan to the chemotherapy regimen resulted in a CR in 12 out 
of 14 patients who had initially achieved PR only. During a median follow-
up time of 30 months, 10 patients progressed, leading to an estimated 3-year 
PFS of 76% and an estimated 3-year overall survival of 100%. Despite rela-
tive frequent grade 3 or 4 haematological toxic effects (neutropenia in 30, 
thrombocytopenia in 36 and anaemia in 13 out of 57 patients), treatment 
was never discontinued and only two patients required hospitalization due 
to febrile neutropenia.  
In a phase II trial conducted by Hainsworth et al [13], ibritumomab tiuxetan 
after short-course chemoimmunotherapy with rituximab either in combina-
tion with CHOP or CVP was evaluated in 41 patients. The study population 
was similar to the studies mentioned above, except that the majority of pa-
tients (83%) had either low or intermediate FLIPI scores. CR/CRu in-
creased from 30% after chemoimmunotherapy to 72% after the administra-
tion of Zevalin® and only one patient progressed. At the end of the follow-
up, median PFS was not yet reached but estimated 3- and 5-year PFS rates 
were 75% and 64%, respectively. Reported side-effects were consistent with 
the other studies.  
7 Estimated costs 
In Austria, one kit of radiopharmaceutical preparation for Zevalin® infu-
sion, containing one vial of 3.2 mg (1,6mg/ml), is € 10,733.- [14]. As treat-
ment is delivered only once, these costs display the overall costs for ibritu-
momab therapy but have to be added to expenses for induction therapies, as 
well as the concomitant rituximab therapy. 
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8 Ongoing research 
Two phase III studies were identified on clinical.trials.gov [15]:  
NCT00491491: adding Zevalin® to the conditioning regimen given prior to 
carmustine, etoposide, cytarabine and melphalan (BEAM) high-dose chemo-
therapy and autologous stem cell transplantation in patients with aggressive 
lymphoma.  
NCT00463463 which is not yet recruiting eligible patients. The aim is to 
compare Zevalin® and BEAM high‐dose chemotherapy versus BEAM alone to 
determine  the potential  of  Zevalin®  radioimmunotherapy  in  improving  the 
outcome of autologous stem‐cell transplantation.   
Additionally, several phase I and phase II studies were found. Research top-
ics include ibritumomab tiuxetan for the treatment of FL in combination 
with various chemotherapy regimens, with chemotherapy prior to autolo-
gous stem cell transplantation and ibritumomab tiuxetan as first-line ther-
apy for patients with FL or for FL of grade 1 or 2. Furthermore, the use of 
Zevalin® is under evaluation in other NHL entities such as mantle cell NHL 
[16] or diffuse large B-cell lymphomas [17].    
9 Commentary 
Based on one phase III study, the EMEA granted market authorization for 
Zevalin® for consolidation therapy after remission induction in previously 
untreated patients with FL in April 2008. Despite the long period of time 
since market approval, reasons hampering the widespread use of Zevalin®  
might include uncertainty about delayed adverse effects, such as secondary 
malignancies or bone marrow damage, the necessary treatment shift from 
haematologists to nuclear medicine physicians [10] and the limited avail-
ability of specialized centres with the required technical conditions for 
treatment delivery in Austria.  
One phase III study showed substantial improvements in PFS of approxi-
mately 2 years in patients receiving Zevalin® after first remission in com-
parison to no further treatment. Additionally, 77% of patients who had ini-
tially achieved PR after induction chemotherapy converted to CR/CRu. 
These findings were consistent even if patients were stratified by response to 
first-line induction therapy and, in the majority, regardless of the type of in-
duction chemotherapy. In all studies presented in this report, the most 
common side effects were transient hematologic toxicities, which occurred 
frequently but were manageable with platelet infusions and red blood cell 
transfusions. However, the risk of potential long-term adverse effects (e.g. 
myelodysplastic syndromes or acute myeloid leukaemia) associated with the 
exposure to ionising radiation, has not yet been clarified [18]. Additionally, 
no differences between the two groups could have been shown in terms of 
overall survival, probably due to the relative short observation period. 
Health-related quality of life and pain scores were also not improved by 
Zevalin®. 
 
ongoing trials assess 
Zevalin® for other 
indications/other NHL 
entities 
 
 
despite EMEA market 
authorization in 2008, 
widespread use is 
hampered  in Austria 
 
 
improvements in 
progression-free 
survival by about 2 
years 
 
 
most common side-
effects were transient 
hematologic toxicities 
 
 LBI-HTA | 2009 11 
Even though the study was not designed to detect differences based on ini-
tial chemotherapy regimens, the authors present results for the individual 
subgroups.  For the considerably small group of patients pre-treated with ri-
tuxmab (overall only 59 patients), median PFS was not superior for the in-
tervention compared to the control group. Since current FL therapy regi-
mens most frequently incorporate rituximab, the additional benefit of ibri-
tumomab tiuxetan for patients pre-treated with rituximab remains unclear 
[10]. On the one hand, the impressive extension of overall PFS might also 
hold true for patients pre-treated with rituximab. On the other hand, adding 
ibritumomab tiuxetan increases treatment costs, probably even at the ex-
pense of an augmented risk of adverse events and without any additional 
benefit.  
Additional to data legitimising the use of this combination, the comparison  
of ibritumomab tiuxetan with rituximab is of further interest. As mainte-
nance therapy with rituximab has also shown impressive results [19], clini-
cal benefits either for rituximab based maintenance therapy or for ibritu-
momab tiuxetan consolidation therapy might be established [8, 10]. Fur-
thermore, the importance of Zevalin® might increase, once results of ongo-
ing trials evaluating it as first-line therapy and in other B-NHL subtypes 
and clinical settings become available. Zevalin® might also play a role in pa-
tients unsuitable for extended conventional chemotherapies. 
10 Commentary – German 
Basierend auf einer Phase III Studie erteilte die EMEA im April 2008 die 
europäische Marktzulassung für Zevalin®  als  Konsolidierungstherapie  bei 
zuvor unbehandelten PatientInnen mit  follikulärem Lymphom (FL), die auf 
eine  Induktionstherapie  angesprochen hatten. Obwohl  Ibritumomab Tiuxe‐
tan daher schon längere Zeit zugelassen ist, könnten Faktoren wie Unsicher‐
heit  bezüglich  der  Langzeitfolgen  (sekundäre  Malignome,  Knochenmarks‐
schäden) oder der notwendige Zuständigkeitswechsel von OnkologInnen zu 
NuklearmedizinerInnen,  ebenso  wie  die  begrenzte  Anzahl  an  Zentren  mit 
entsprechender technischer Einrichtung, die breite Anwendung in der klini‐
schen Praxis in Österreich limitiert haben [10] .  
In der oben erwähnten Phase III Studie, wurde durch Ibritumomab Tiuxetan 
als Konsolidierungstherapie im Vergleich zu keiner Konsolidierungstherapie 
das  mediane  progressionsfreie  Überleben  (PFS)  um  beträchtliche  2  Jahre 
verlängert. Zusätzlich konnte in 77% der PatientInnen, bei denen nach  der 
Induktionstherapie  nur  eine  Teilremission  (PR)  erzielt  worden  war,  eine 
komplette Remission  (CR/CRu) erreicht werden. Ähnliche Ergebnisse wur‐
den auch in einer Subgruppen‐Analyse gefunden, in der Patienten einerseits 
nach  Therapieansprechen  auf  die  initiale  Chemotherapie  und  andererseits 
nach Art des verabreichten Chemotherapieregimes stratifiziert wurden.  
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Die  am  häufigsten  beobachteten  unerwünschten  Nebenwirkungen  waren 
transiente  hämatologische  Reaktionen,  die,  wenn  auch  schwerwiegend, 
durch  konservative  Maßnahmen  beherrschbar  waren.    Unklar  hingegen 
bleiben  potentielle,  durch  Strahlungsschäden  verursachte  Langzeitfolgen, 
wie  etwa  die  Entstehung myelodysplastischer  Syndrome  oder  akuter mye‐
loischer  Leukämien  [18].  Möglicherweise  bedingt  durch  die  relative  kurze 
Beobachtungsdauer der Studie sind Daten zu verbesserter Überlebensdauer 
ausständig. Keine Unterschiede zwischen den beiden Gruppen wurden auch 
in Bezug auf Lebensqualität oder Schmerzsymptomatik gefunden.  
Obwohl diese Studie nicht darauf ausgerichtet war, signifikante Unterschie‐
de  zwischen  den  einzelnen  Chemotherapieregimes  nachweisen  zu  können, 
so wurden doch PFS Ergebnisse  für  die  einzelnen  Subgruppen  präsentiert.  
Wie erwähnt, konnte Ibritumomab Tiuxetan in Kombination mit den meisten  
Therapieregimes bessere Ergebnisse erzielen, als die Vergleichsgruppe. Für 
die  relative  kleine  Gruppe  von  PatientInnen  (insgesamt  59  Personen),  die 
mit  einer  Rituximab  Erstlinien‐Therapie  behandelt  worden  waren,  zeigte 
sich jedoch kein Unterschied hinsichtlich PFS. Da aber moderne therapeuti‐
sche Strategien zur Behandlung von FL durchwegs Rituximab inkorporieren, 
bleibt der klinische Nutzen von Ibritumomab Tiuxtan  nach einer Rituximab 
beinhaltenden  Induktionstherapie unklar  [10]. Mögliche Konsequenz  ist ei‐
nerseits,  dass mit  Rituximab  vorbehandelte  PatientInnen  von  der  zusätzli‐
chen Verabreichung von Zevalin® profitieren, oder aber, dass lediglich höhe‐
re Kosten und vermehrte Nebenwirkungen entstehen, diese aber nicht in zu‐
sätzlichem klinischen Nutzen für PatientInnen resultieren.  
Zusätzlich zu weiteren Studien, die den Einsatz dieser Kombination rechtfer‐
tigenden,  ist  auch der Vergleich zwischen  den beiden Substanzen von  Inte‐
resse: da mit Rituximab als Erhaltungstherapie ebenfalls vielversprechende 
Resultate erzielt werden konnten [19], stellt sich nun die Frage, ob der Kon‐
solidierungstherapie mit Ibritumomab Tiuxtan oder der Erhaltungstherapie 
mit Rituximab der Vorzug gegeben werden sollte [8, 10]. Allerdings könnte 
Ibritumomab Tiuxetan  in Zukunft auch als Erstlinien‐Therapie zum Einsatz 
kommen – diesbezügliche Studien sind bereits im Gange.  Daneben wird der 
Einsatz von Zevalin® bei anderen B-NHL Subtypen und klinischen Situati-
onen untersucht. Eine wichtige Rolle könnte in Zukunft auch der Einsatz 
bei PatientInnen, die für eine prolongierte konventionelle Chemotherapie 
ungeeignet sind, spielen.    
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